4 - CARDINAL HEALTH INC (0000721371) (Issuer)

4 - CARDINAL HEALTH INC (0000721371) (Issuer)

4 - CARDINAL HEALTH INC (0000721371) (Issuer)

4 - CARDINAL HEALTH INC (0000721371) (Issuer)

4 - CARDINAL HEALTH INC (0000721371) (Issuer)

4 - CARDINAL HEALTH INC (0000721371) (Issuer)

4 - CARDINAL HEALTH INC (0000721371) (Issuer)

4 - CARDINAL HEALTH INC (0000721371) (Issuer)

4 - CARDINAL HEALTH INC (0000721371) (Issuer)

4 - CARDINAL HEALTH INC (0000721371) (Issuer)

8-K - CARDINAL HEALTH INC (0000721371) (Filer)

424B5 - CARDINAL HEALTH INC (0000721371) (Filer)

FWP - CARDINAL HEALTH INC (0000721371) (Subject)

424B3 - CARDINAL HEALTH INC (0000721371) (Filer)

8-K - CARDINAL HEALTH INC (0000721371) (Filer)

S-8 POS - CARDINAL HEALTH INC (0000721371) (Filer)

S-8 POS - CARDINAL HEALTH INC (0000721371) (Filer)

S-8 POS - CARDINAL HEALTH INC (0000721371) (Filer)

8-K - CARDINAL HEALTH INC (0000721371) (Filer)

10-Q - CARDINAL HEALTH INC (0000721371) (Filer)

Next generation of the Kendall™ SCD Series delivers an all-in-one solution for deep vein thrombosis and pulmonary embolism prevention DUBLIN, Ohio, Nov. 20, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today the U.S. launch of its Kendall SCD SmartFlow™ Compression System, the next generation of the Kendall™ Compression Series offering an enhanced clinician and patient experience. Featuring clinically proven technology that delivers customized, intermittent pneumatic compression (IPC) to increase blood flow1 in at-risk patients, the Kendall SCD SmartFlow™ System is designed to help prevent venous thromboembolism (VTE) events, as well as enhance blood circulation and treat pain a

Cardinal Health to acquire Advanced Diabetes Supply Group Court Square Capital Partners ("Court Square"), a leading middle-market private equity company, announced today it has entered a definitive agreement in the sale of Advanced Diabetes Supply® Group ("ADSG", or "Company") to Cardinal Health (NYSE:CAH). Court Square originally acquired the Company in December 2020. Headquartered in Carlsbad, CA, ADSG is a national distributor of Durable Medical Equipment ("DME") specializing in diabetes supplies. The Company currently serves approximately 500,000 patients and specializes in the home delivery of diabetes products including continuous glucose monitoring ("CGM") devices and other testi

Southlake, Texas, Nov. 11, 2024 (GLOBE NEWSWIRE) -- GI Alliance (GIA) announced today that it has entered into a definitive agreement with Cardinal Health (NYSE:CAH) through which Cardinal Health will acquire a majority stake in GIA, a physician-led, national management services organization supporting independent gastroenterology practices from a combination of GIA physician owners and funds managed by affiliates of Apollo (NYSE:APO).  The transaction values GI Alliance at $3.9 billion. "GI Alliance and Cardinal Health are aligned in our shared vision to build a physician-led, national specialty healthcare platform that will be the preferred choice for patients seeking dependable, high

Acquisition of a majority stake in GI Alliance, the country's leading gastroenterology management services organization, to accelerate Cardinal Health's multi-specialty growth strategy Acquisition of the Advanced Diabetes Supply Group, a leading national direct-to-patient provider of diabetes medical supplies, to accelerate Cardinal Health's at-Home Solutions growth strategyCompany announces plan to hold Investor Day in June 2025DUBLIN, Ohio, Nov. 11, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that it has entered into definitive agreements to acquire two companies that accelerate Cardinal Health's strategic growth areas and that will enhance patient care. The company als

DUBLIN, Ohio, Nov. 5, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on January 15, 2025 to shareholders of record at the close of business on January 2, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuc

Revenue decreased 4% to $52.3 billion; revenue increased 15% excluding the impact of the previously communicated large customer contract expirationGAAP1 operating earnings were $568 million; GAAP diluted EPS was $1.70Non-GAAP operating earnings increased 12% to $625 million, driven by significant growth in Pharmaceutical and Specialty Solutions segment profitNon-GAAP diluted EPS increased 9% to $1.88Fiscal year 2025 non-GAAP EPS guidance2 raised to $7.75 to $7.90, from $7.55 to $7.70DUBLIN, Ohio, Nov. 1, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported first quarter fiscal year 2025 revenue of $52.3 billion, a decrease of 4% from the first quarter of fiscal year 2024. First qu

New facility in Boylston increases U.S. warehouse capacity and expands specialized handling capabilities DUBLIN, Ohio, Oct. 29, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today the grand opening of its new distribution center in Boylston, Massachusetts, supporting its U.S. Medical Products and Distribution business. The facility provides healthcare customers in Massachusetts, New Hampshire, Rhode Island, Maine, Vermont and Eastern Connecticut with modernized operations and expanded capacity, as well as specialized handling capabilities for products with strict storage requirements, available early 2025. At nearly 317,000 square feet, the new facility has replaced the Cardinal

LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has entered into a multi-year exclusive U.S. agreement with Cardinal Health (NYSE:CAH),. Under the agreement, Cardinal Health will have exclusive rights to sell T2 Biosystems' FDA-cleared direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens, including the T2Dx® Instrument, the T2Bacteria® Panel, and the T2Candida® Panel. "We are thrilled to have entered into a distribution agreement with Cardinal Health that will make them the exclusive distrib

DUBLIN, Ohio, Sept. 24, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release first-quarter financial results for its fiscal year 2025 on November 1, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern. To access the webcast and corresponding slide presentation, visit Cardinal Health's Investor Relations page. No access code is required. Presentation slides and a webcast replay will be available on the Investor Relations page for 12 months. About Cardinal Health Cardin

Transaction demonstrates Cardinal Health's continued strategic investment in specialty and oncology, underscores commitment to independent community healthcare providers Accelerates the development of Navista oncology practice alliance, adding more than 100 providers at more than 50 community-based sites delivering broad-reaching oncology and urology care across 10 statesDUBLIN, Ohio, Sept. 20, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that it has entered into a definitive agreement to acquire Integrated Oncology Network (ION), a physician-led independent community oncology network, for $1.115B in cash. ION includes more than 50 practice sites in 10 states representing

DUBLIN, Ohio, Feb. 28, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1. Mr. Azelby joins the board with over 30 years of experience, including as a Chief Executive Officer and board member for large, matrixed organizations in the biopharmaceutical, oncology and other specialty industries. Mr. Azelby has previously served as President and Chief Executive Officer of Eliem Therapeutics, and prior to Eliem, he was the Chief Executive Officer of Alder BioPharmac

Revenue increased 13% to $49.6 billionGAAP1 operating earnings were $137 million, GAAP diluted EPS were $0.40Non-GAAP operating earnings decreased 20% to $423 million due to a decline in Medical segment profit, partially offset by an increase in Pharmaceutical segment profit; non-GAAP diluted EPS decreased 7% to $1.20Company reaffirmed fiscal year 2023 non-GAAP EPS guidanceDUBLIN, Ohio, Nov. 4, 2022 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported first quarter fiscal year 2023 revenues of $49.6 billion, an increase of 13% from the first quarter of last year. First quarter GAAP operating earnings were $137 million, including a non-cash, pre-tax goodwill impairment charge of $154 mil

Adds Four New Independent Directors to the Board Forms New Business Review Committee to Evaluate Portfolio and Operations DUBLIN, Ohio, Sept. 6, 2022 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced initiatives aimed at positioning the Company for long-term success, building on Cardinal Health's previously announced growth plans. These initiatives have benefited from input received from Elliott Investment Management L.P. ("Elliott").  In connection with these initiatives, Elliott has also entered into a cooperation agreement with Cardinal Health, and Elliott's Steven Barg will join the Company's Board of Directors.

CAMBRIDGE, MA / ACCESSWIRE / April 11, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that Jorge Gomez will join Moderna as Chief Financial Officer, effective Monday, May 9, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer, Stéphane Bancel."I am pleased to welcome Jorge to Moderna as our Chief Financial Officer and as a member of the Executive Committee," said Mr. Bancel. "As we grow and scale the company globally, Jorge's experience leading the financial functions of multinational healthcare companies will be an asset to our team. Jorge's passion for sustainabilit

Believes Nominees Have the Independent Perspectives, Differentiated Real Estate Investment Experience and Shareholder-Focused Mindsets Needed to Help Reverse Lexington's Chronic Underperformance Objective and Independent New Voices are Needed in the Boardroom to Oversee Leadership Transition Process and Full Review to Determine the Right Path Forward for LXP LXP's Total Shareholder Returns Have Underperformed Proxy Peers and Industrial Peers by Nearly 500% During CEO's 18-year Tenure1 Today Land & Buildings Investment Management, LLC (together with its affiliates, "Land & Buildings"), a significant shareholder of Lexington Realty Trust ("LXP," "Lexington" or the "Company") (NYSE:LXP), an

CANTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Jon Giacomin to the Company's Board of Directors, effective May 7, 2021. The Company also announced that Wayne Mackie resigned as a member of the Company's Board of Directors effective May 7, 2021. Mr. Mackie's resignation was not due to any disagreement with the Company on any matter relating to its operations, policies or practices. "Jon is a proven leader who brings signifi

NEW YORK & LOS ANGELES--(BUSINESS WIRE)--RMG Acquisition Corp. (the “Company”) announced the nomination of Paul Williams for election at a special meeting of stockholders of the Company to serve on the board of directors of the combined company upon consummation of the previously announced merger between the Company and Romeo Systems, Inc. (“Romeo Power”). Prior to his retirement in 2018, Mr. Williams served as a Partner and Managing Director of Major, Lindsey & Africa, LLC, an executive recruiting firm, where he conducted searches for board members, CEOs and senior legal executives from 2005 to 2018. He also served as Director of Global Diversity Search, assisting legal organizati

Citigroup analyst Daniel Grosslight maintains Cardinal Health (NYSE:CAH) with a Neutral and lowers the price target from $115 to $107.

Cardinal Health's (NYSE:CAH) short percent of float has fallen 17.69% since its last report. The company recently reported that it has 6.12 million shares sold short, which is 3.35% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.18 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short intere

Evercore ISI Group analyst Elizabeth Anderson maintains Cardinal Health (NYSE:CAH) with a In-Line and lowers the price target from $115 to $105.

Baird analyst Eric Coldwell maintains Cardinal Health (NYSE:CAH) with a Outperform and raises the price target from $129 to $130.

First, Claudia Post oversaw the safe delivery of eyeballs, kidneys and other organs. Today? Her specialty is cannabis. Most recently, she launched Scarlet Express with financial backing from Ben Sopranzetti, vice chair of the Department of Finance and Economics at Rutgers Business School. The Philadelphia-based startup is a state-approved, closed-loop delivery organization providing discreet, secure and expert cannabis supply chain management nationwide. And Post is the perfect person for this type of venture. A serial entrepreneur, Post launched MOST Consulting Group, a one-stop shop for cannabis marketing and advertising, and founded Diamond Transportation Group, a same-day, ti

Cardinal Health (NYSE:CAH) has outperformed the market over the past 5 years by 2.37% on an annualized basis producing an average annual return of 15.18%. Currently, Cardinal Health has a market capitalization of $23.86 billion. Buying $1000 In CAH: If an investor had bought $1000 of CAH stock 5 years ago, it would be worth $2,026.95 today based on a price of $97.96 for CAH at the time of writing. Cardinal Health's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content

Cardinal Health (NYSE:CAH) has outperformed the market over the past 5 years by 4.45% on an annualized basis producing an average annual return of 17.8%. Currently, Cardinal Health has a market capitalization of $25.27 billion. Buying $1000 In CAH: If an investor had bought $1000 of CAH stock 5 years ago, it would be worth $2,305.49 today based on a price of $103.77 for CAH at the time of writing. Cardinal Health's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content

Cardinal Health (NYSE:CAH) has outperformed the market over the past 5 years by 4.09% on an annualized basis producing an average annual return of 17.12%. Currently, Cardinal Health has a market capitalization of $23.86 billion. Buying $1000 In CAH: If an investor had bought $1000 of CAH stock 5 years ago, it would be worth $2,235.91 today based on a price of $97.96 for CAH at the time of writing. Cardinal Health's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content

Cardinal Health's (NYSE:CAH) short percent of float has fallen 5.36% since its last report. The company recently reported that it has 8.05 million shares sold short, which is 4.41% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.63 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interes

UnitedHealth Group‘s (NYSE:UNH) OptumRx unit has a new pricing model to help manage drug costs for insurers.  Starting next year, the OptumRx Clear Trend Guarantee will offer value-based pricing for drugs. It will integrate costs from various sources such as retail pharmacies, home delivery, specialty drugs, and rebates. Value-based pricing means that payments for medicines will be linked to patient outcomes. This involves insurers, pharmaceutical companies, and pharmacy benefit management (PBMs) like OptumRx. Related: Analysts Raises Forecasts On UnitedHealth On Controlled Growth Strategy After Cyber Hack. This model aims to provide a more transparent and predictable drug pr

Leerink Partners initiated coverage of Cardinal Health with a rating of Outperform and set a new price target of $125.00

Argus upgraded Cardinal Health from Hold to Buy

Barclays initiated coverage of Cardinal Health with a rating of Overweight and set a new price target of $117.00

Wells Fargo initiated coverage of Cardinal Health with a rating of Underweight and set a new price target of $96.00

Evercore ISI downgraded Cardinal Health from Outperform to In-line and set a new price target of $100.00

Citigroup initiated coverage of Cardinal Health with a rating of Neutral and set a new price target of $77.00

Robert W. Baird upgraded Cardinal Health from Neutral to Outperform and set a new price target of $94.00 from $87.00 previously

BofA Securities upgraded Cardinal Health from Underperform to Neutral and set a new price target of $80.00 from $64.00 previously

Morgan Stanley resumed coverage of Cardinal Health with a rating of Overweight and set a new price target of $76.00 from $70.00 previously

Barclays downgraded Cardinal Health from Overweight to Equal Weight